共 50 条
- [1] Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trialDIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1040 - 1044Jorgensen, Peter G.Jensen, Magnus T.Mensberg, PernilleStorgaard, HeidiNyby, SigneJensen, Jan S.Knop, Filip K.Vilsboll, Tina
- [2] Effect on cardiac function of exercise combined with glucagon-like peptide-I receptor agonist treatment: a randomised double-blind placebo-controlled clinical trialDIABETOLOGIA, 2016, 59 : S368 - S369Jorgensen, P. G.Jensen, M. T.Mensberg, P.Storgaard, H.Nyby, S.Jensen, J. S.Kiens, B.Richter, E. A.Knop, F. K.Vilsboll, T.
- [3] Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trialNUTRITION, 2018, 55-56 : 125 - 130Lertrit, AmornpanSrimachai, SasineeSaetung, SuneeChanprasertyothin, SuwanneeChailurkit, La-orAreevut, ChatvaraKatekao, PornalatOngphiphadhanakul, BoonsongSriphrapradang, Chutintorn
- [4] Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover studyEBIOMEDICINE, 2024, 107Lengsfeld, SophiaProbst, LeilaEmara, YaraWerlen, LauraVogt, Deborah R.Bathelt, CemileBaur, FabienneCaviezel, BridaVukajlovic, TanjaFischer, ManuelWinzeler, Bettina
- [5] The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity A Randomized, Placebo-Controlled, Clinical TrialJAMA PEDIATRICS, 2013, 167 (04) : 355 - 360Kelly, Aaron S.Rudser, Kyle D.Nathan, Brandon M.Fox, Claudia K.Metzig, Andrea M.Coombes, Brandon J.Fitch, Angela K.Bomberg, Eric M.Abuzzahab, M. Jennifer
- [6] THE EFFECT OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE ON 24-H BLOOD PRESSURE VARIATION: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CROSS OVER STUDYJOURNAL OF HYPERTENSION, 2016, 34 : E42 - E43Kumarathurai, P.Anholm, C.Kristiansen, O. K.Nielsen, O. W.Haugaard, S. B.Sajadieh, A.
- [7] Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trialDIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2374 - 2384Bojer, Annemie StegeSorensen, Martin HeynBjerre, JennyGaede, PeterVejlstrup, NielsMadsen, Per Lav
- [8] Is Double-Blinding Achievable in Placebo-Controlled Trials with the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide?DIABETES, 2017, 66 : A302 - A303Foghsgaard, SigneVedtofte, LouiseBahne, EmilieAndreasen, CamillaChristiansen, Liselotte K.Clausen, Tine D.Svare, Jens A.Mathiesen, Elisabeth R.Damm, PeterGluud, Lise L.Knop, Filip K.Vilsboll, Tina
- [9] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyCardiovascular Diabetology, 15Preman KumarathuraiChristian AnholmOlav W. NielsenOle P. KristiansenJens MølvigSten MadsbadSteen B. HaugaardAhmad Sajadieh
- [10] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyCARDIOVASCULAR DIABETOLOGY, 2016, 15Kumarathurai, PremanAnholm, ChristianNielsen, Olav W.Kristiansen, Ole P.Molvig, JensMadsbad, StenHaugaard, Steen B.Sajadieh, Ahmad